AstraZeneca has had a setback in its late-stage oncology pipeline, after AKT inhibitor ceralasertib, given in combination with cancer immunotherapy Imfinzi, failed to extend survival in a lung cancer ...

Our team of savvy editors independently handpicks all recommendations. If you make a purchase through our links, we may earn a commission. Deals and coupons were accurate at the time of publication ...